Skip to content

Toll-like Receptor 7 and Interferon-α Synergy Establishes a Positive Feedback Loop to Potentiate Antiviral Immunity in Chronic Hepatitis B.

Oct 2026 · Antiviral Research · pp. 106553 · 0 citations · 39 references
Medicine

Abstract

Background

AND

Objectives

Current therapies for chronic hepatitis B (CHB) rarely achieve functional cure, underscoring the need for novel immunotherapies. Toll-like receptor 7 (TLR7), a key innate immune sensor, has emerged as a major drug development focus. This study aims to characterize stage-specific TLR7 expression and functions in CHB, investigate its association with antiviral therapy response, and evaluate synergistic effects of TLR7 activation combined with interferon-α (IFN-α).

Methods

We conducted cross-sectional and longitudinal clinical analyses of CHB patients, complemented by in vitro functional assays using peripheral blood mononuclear cells (PBMCs) and purified B cells, and an in vivo HBV mouse model.

Results

TLR7 expression in PBMCs was downregulated in immunotolerant and inactive carriers but elevated in immune-active (IA) patients, positively correlated with serum ALT. TLR7 activation induced IFN-α-mediated HBV suppression, with IA patient-derived PBMCs exhibiting enhanced antiviral activity. Notably, IFN-α dose-dependently upregulated TLR7 expression, revealing a positive feedback loop between TLR7 and IFN-α. Clinically, sustained TLR7 upregulation during pegylated IFN-α therapy predicted virological response. As the primary TLR7-expressing subset, B cells exhibited enhanced proliferation, activation, cytokine production, and antibody secretion upon combined TLR7 ligand (TLR7-L)/IFN-α stimulation. In an HBV mouse model, TLR7-L/IFN-α combination therapy synergistically suppressed HBsAg and enhanced CD8+ T cell functionality.

Conclusions

This study identifies a candidate self-reinforcing TLR7-IFN-α positive feedback loop in CHB that exhibits stage-specific dynamics and predicts treatment response. The synergistic effects of TLR7 and IFN-α support a threshold model of immune activation and provide a mechanistic rationale for combination immunotherapies aiming for functional cure.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.